Pluvicto is a targeted radioactive therapy that finds and destroys prostate cancer cells wherever they are in the body. It works by attaching to a protein called PSMA that sits on the surface of most prostate cancer cells, then delivering a short-range burst of radiation that kills those cells from the inside. The FDA approved it for men with metastatic castration-resistant prostate cancer (mCRPC) whose tumors test positive for PSMA.
The Lock-and-Key Targeting System
Prostate cancer cells produce unusually high levels of a surface protein called PSMA (prostate-specific membrane antigen). Normal prostate tissue makes some PSMA too, but cancer cells express far more of it. This difference is what makes Pluvicto possible.
The drug has two connected parts: a small molecule that recognizes and locks onto PSMA, and a radioactive atom (lutetium-177) riding along with it. Once injected into a vein, the drug circulates through the bloodstream and sticks to PSMA-expressing cells throughout the body. The Society of Nuclear Medicine and Molecular Imaging describes it as a lock-and-key system: PSMA is the lock on the cancer cell’s surface, and the drug is the key. This means it can reach metastatic tumors in bones, lymph nodes, or organs without needing to know exactly where they are beforehand.
How the Radiation Kills Cancer Cells
Once the drug binds to PSMA and enters the cancer cell, the lutetium-177 emits beta radiation. Beta particles are high-energy electrons that damage DNA strands in the cell, triggering cell death. The critical feature is range: beta radiation from lutetium-177 travels only a few millimeters from where it lands. That’s far enough to destroy the target cell and some of its immediate neighbors, but short enough to largely spare healthy tissue farther away.
This “crossfire” effect means even nearby cancer cells that express less PSMA can still be hit by radiation from a neighboring cell that absorbed the drug. At the same time, the limited range is why the treatment is considered more targeted than traditional external beam radiation or chemotherapy.
Qualifying for Treatment
Not every prostate cancer patient is eligible. Your tumors need to show strong PSMA expression, confirmed through a special PET scan using a tracer like Locametz (gallium-68 gozetotide). During the scan, doctors compare how much tracer your tumors absorb relative to your liver. In the landmark VISION trial, patients qualified only if their tumor uptake exceeded liver uptake, with no significant disease sites that failed to light up on the scan.
As of March 2025, the FDA approves Pluvicto for two groups of men with PSMA-positive mCRPC: those who have already received both hormonal therapy and chemotherapy, and a newer, expanded group who have been treated with hormonal therapy alone and are considered appropriate to delay chemotherapy.
What Treatment Looks Like
Pluvicto is given as an intravenous infusion, typically at a specialized nuclear medicine center. The standard protocol is one dose every six weeks for up to six cycles, though treatment may stop earlier if the cancer progresses or side effects become too severe.
Because the drug is radioactive, there are brief precautions afterward. Patients are generally allowed to travel home the same day, but are advised to sleep alone for two nights and avoid close contact with children and pregnant women for about one day. The lutetium-177 has a half-life of roughly 6.7 days, so its radioactivity drops steadily and most of the drug is cleared from the body through urine within the first few days.
How Well It Works
The strongest efficacy data comes from patients who had already tried both hormonal therapy and chemotherapy. In the VISION trial, adding Pluvicto to standard care significantly extended survival compared to standard care alone. A separate trial, PSMAfore, tested Pluvicto earlier in the treatment sequence, in men who hadn’t yet received chemotherapy. In that study, median overall survival was about 24.5 months with Pluvicto compared to 23.1 months with a switch in hormonal therapy. That difference was not statistically significant, but the FDA still expanded the approval based on the broader clinical picture, including improvements in the time before the cancer worsened.
Common Side Effects
Because PSMA also appears in small amounts on some healthy tissues, particularly the salivary glands and kidneys, the radiation isn’t perfectly confined to cancer cells. Dry mouth is one of the most recognizable side effects, affecting about 39% of patients in the VISION trial, though it was mild in nearly all cases. Fatigue is even more common, reported by 43% of patients, with about 6% experiencing severe fatigue.
The more medically significant side effects involve blood cell counts. Radiation can suppress the bone marrow, which is where blood cells are made. In the VISION trial:
- Low red blood cells (anemia): 63% of patients overall, 15% with severe drops
- Low white blood cells: 56% overall, 7% severe
- Low lymphocytes (a type of immune cell): 85% overall, 47% severe
- Low platelets: 45% overall, 9% severe
Because of these effects on blood counts, doctors monitor bloodwork before each cycle. If counts drop too low, a dose may be delayed or treatment stopped. Most patients tolerate the full six cycles, but the blood count changes are the main reason some don’t.
Why It Differs From Chemotherapy
Traditional chemotherapy attacks all rapidly dividing cells, which is why it causes widespread side effects like hair loss, nausea, and severe immune suppression. Pluvicto takes a fundamentally different approach. Rather than poisoning fast-growing cells indiscriminately, it uses PSMA as a homing signal to concentrate radiation at the tumor site. The radiation itself does the killing, not a chemical toxin. This is why the side effect profile looks different: dry mouth and blood count changes rather than the nausea and hair loss typically associated with chemo. It also explains why a positive PSMA scan is a hard requirement. Without that target on the cell surface, there’s no lock for the key to fit.